» Articles » PMID: 10406834

Induction of Interleukin-6 Expression by Angiotensin II in Rat Vascular Smooth Muscle Cells

Overview
Journal Hypertension
Date 1999 Jul 16
PMID 10406834
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Recent studies suggest that atherosclerosis is a kind of inflammatory process and that cytokine plays important roles in this process. Although it is generally accepted that angiotensin II (Ang II) plays an important role in atherogenesis, the role of Ang II in cytokine production has not been explored. In this report, we investigated the effect of Ang II on the production of interleukin-6 (IL-6), which is a multifunctional proinflammatory cytokine in rat vascular smooth muscle cells. Ang II significantly increased the expression of IL-6 mRNA and protein in a dose-dependent manner (10(-10) to 10(-6) mol/L). The expression of IL-6 mRNA induced by Ang II showed 2 peaks at 30 minutes and 12 to 24 hours after stimulation. The effect of Ang II on IL-6 release and mRNA expression was completely blocked by an Ang II type 1 receptor antagonist, CV11974; however, an Ang II type 2 receptor antagonist, PD123319, showed no effect. Chelating of intracellular Ca(2+) with BAPTA-AM, inhibition of tyrosine kinase with genistein, and inhibition of mitogen-activated protein kinase kinase with PD98059 completely abolished the effect of Ang II. However, downregulation of protein kinase C by pretreatment with a phorbol ester for 24 hours or a specific protein kinase C inhibitor, calphostin C, did not affect the Ang II-induced expression of IL-6 mRNA. Deletion and mutational analysis of IL-6 gene promoter showed that cAMP-responsive element was important for Ang II-induced IL-6 gene expression. Gel mobility shift assay showed an increase of cAMP-responsive element binding protein by Ang II. These results provide new insights into Ang II signaling and the role of Ang II in the progression of inflammatory changes of blood vessels.

Citing Articles

Radiation Induced Skin Fibrosis (RISF): Opportunity for Angiotensin II-Dependent Intervention.

Boothe P, Kumar V, Kong Y, Wang K, Levinson H, Mu D Int J Mol Sci. 2024; 25(15).

PMID: 39125831 PMC: 11312688. DOI: 10.3390/ijms25158261.


Immunomodulatory Activity of Cytokines in Hypertension: A Vascular Perspective.

Dos Passos R, Santos C, Priviero F, Briones A, Tostes R, Webb R Hypertension. 2024; 81(7):1411-1423.

PMID: 38686582 PMC: 11168883. DOI: 10.1161/HYPERTENSIONAHA.124.21712.


Immune and inflammatory mechanisms in hypertension.

Guzik T, Nosalski R, Maffia P, Drummond G Nat Rev Cardiol. 2024; 21(6):396-416.

PMID: 38172242 DOI: 10.1038/s41569-023-00964-1.


Immunological and biochemical biomarker alterations among SARS-COV-2 patients with varying disease phenotypes in Uganda.

Drago Kato C, Nsubuga J, Niyonzima N, Kitibwa A, Matovu E, Othieno E BMC Infect Dis. 2023; 23(1):857.

PMID: 38057707 PMC: 10701962. DOI: 10.1186/s12879-023-08854-0.


A new immune disease: systemic hypertension.

Copur S, Peltek I, Mutlu A, Tanriover C, Kanbay M Clin Kidney J. 2023; 16(9):1403-1419.

PMID: 37664577 PMC: 10469084. DOI: 10.1093/ckj/sfad059.